Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A

Pain

Volumn 125, Issue 3, 2006, Pages 286-295

  Jakubowski, Moshe ^a   McAllister, Peter J ^b   Bajwa, Zahid H ^a   Ward, Thomas N ^c   Smith, Patty ^a   Burstein, Rami ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Dartmouth Hitchcock Medical Center ^*

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Headache; Nociceptors; Pain; Trigeminal

Indexed keywords

BOTULINUM TOXIN A; PROMETHAZINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE AURA; NAUSEA; NECK MUSCLE; NEUROLOGIC DISEASE; PAIN; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33750710500     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.09.012     Document Type: Article

References (44)

1. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26 (2005) 785-793
2. Berweck S., and Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 19 Suppl. 8 (2004) S162-S167
3. Binder W.J., Brin M.F., Blitzer A., Schoenrock L.D., and Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123 (2000) 669-676
4. 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 103 (1986) 521-534
5. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 103 (1986) 535-544
6. Blersch W., Schulte-Mattler W.J., Przywara S., May A., Bigalke H., and Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205 (2002) 59-63
7. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 43 (2003) 853-860
8. Burstein R., Yamamura H., Malick A., and Strassman A.M. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 79 (1998) 964-982
9. Burstein R., Cutrer F.M., and Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123 (2000) 1703-1709
10. Burstein R., Yarnitsky D., Goor-Aryeh I., Ransil B.J., and Bajwa Z.H. An association between migraine and cutaneous allodynia. Ann Neurol 47 (2000) 614-624
11. Chen J.J., and Swope D.M. Essential tremor: diagnosis and treatment. Pharmacotherapy 23 (2003) 1105-1122
12. Comella C.L., Jankovic J., and Brin M.F. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 55 (2000) S15-S21
13. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004) 125-133
14. Defazio G., and Livrea P. Primary blepharospasm: diagnosis and management. Drugs 64 (2004) 237-244
15. Dodick D.W., Mauskop A., Elkind A.H., DeGryse R., Brin M.F., and Silberstein S.D. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45 (2005) 315-324
16. Dolly J.O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 43 (2003) s16-s24
17. Durham P.L., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 (2004) 35-42 discussion 42-3
18. Evers S., Vollmer-Haase J., Schwaag S., Rahmann A., Husstedt I.W., and Frese A. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 24 (2004) 838-843
19. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278 (2003) 1363-1371
20. Fruhstorfer H., Lindblom U., and Schmidt W.C. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 39 (1976) 1071-1075
21. Harrison J.L., and Davis K.D. Cold-evoked pain varies with skin type and cooling rate: a psychophysical study in humans. Pain 83 (1999) 123-135
22. Headache-Classification-Committee-of-the-International-Headache-Society, Classification and diagnosis criteria for headache disorders, cranial neuralgia and facial pain, Cephalalgia, 8 (1988) 1-92.
23. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 19 Suppl. 8 (2004) S109-S115
24. Jensen K., Tuxen C., and Olesen J. Pericranial muscle tenderness and pressure-pain threshold in the temporal region during common migraine. Pain 35 (1988) 65-70
25. 2+-induced changes in SNAREs and synaptotagmin I correlate with triggered exocytosis from chromaffin cells: insights gleaned into the signal transduction using trypsin and botulinum toxins. J Cell Sci 115 (2002) 2791-2800
26. Lawrence G.W., and Dolly J.O. Multiple forms of SNARE complexes in exocytosis from chromaffin cells: effects of Ca(2+), MgATP and botulinum toxin type A. J Cell Sci 115 (2002) 667-673
27. Lindblom U. Analysis of abnormal touch, pain, and temperature sensation in patients. In: Boivie J., Hansson P., and Lindblom U. (Eds). Touch temperature and pain in health and disease: mechanism and assesments Vol. 3 (1994), IASP press, Seattle 63-84
28. Marjama-Lyons J., and Koller W. Tremor-predominant Parkinson's disease. Approaches to Treatment, Drugs Aging 16 (2000) 273-278
29. Olesen J., Goadsby P., Ramadan N.M., Tfelt-Hansen P., and Welch K.M.A. The Headaches (2005), Lippincott Williams & Wilkins, Philadelphia
30. Ondo W.G., Vuong K.D., and Derman H.S. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 24 (2004) 60-65
31. Oshinsky M., Poso-Rosich P., Luo J., Hyman S., and Silberstein S.D. Botulinum toxin A blocks sensitization of neurons in the trigeminal nucleus caudalis. Cephalalgia 24 (2004) 781
32. Selby G., and Lance J.W. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatr (1960) 23-32
33. Siegel S. Nonparametric statistics for the behavioral sciences (1956), McGrow-Hill Kogakusha, Tokyo 312 pp
34. Silberstein S., Mathew N., Saper J., and Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40 (2000) 445-450
35. Silberstein, SD, Olesen, J, Bousser, MG, Diener, HC, Dodick, D, First, M, et al., The International Classification of Headache Disorders, 2nd Edition (ICHD-II) - revision of criteria for 8.2 Medication-overuse headache, Cephalalgia, 25 (2005) 460-5.
36. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33 (1981) 155-188
37. Strigo I.A., Carli F., and Bushnell M.C. Effect of ambient temperature on human pain and temperature perception. Anesthesiology 92 (2000) 699-707
38. Tepper S.J., Bigal M.E., Sheftell F.D., and Rapoport A.M. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache 44 (2004) 794-800
39. Tfelt-Hansen P., Lous I., and Olesen J. Prevalence and significance of muscle tenderness during common migraine attacks. Headache 21 (1981) 49-54
40. Tilton A.H. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol 11 (2004) 58-65
41. Troost B.T. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev Neurother 4 (2004) 27-31
42. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
43. Wolff H.G., Tunis M.M., and Goodell H. Studies on migraine. Arch Intern Med 92 (1953) 478-484
44. Yarnitsky D. Quantitative sensory testing. Muscle Nerve 20 (1997) 198-204